title: Breast Implant and Anaplastic Large Cell Lymphoma Meta-Analysis.
abstract: Recent studies have shown a relationship between lymphoma and breast implants. We performed a meta-analysis about this problem. We found 80 cases, 50 of which were reported in the United States (62.5%). The average age was 52 years. The average time between breast implant surgery and lymphoma was 11 years. Forty-one percent of the breast implants were silicone, 42.19% were saline and 15.8% were unknown. The coverage of the breast implants was texturized in 21.3% and unknown in 78%. The most common brands were McGhan and Mentor. In 72.6% of the cases, the brand was unknown. The clinical findings were seroma (67.33%), nodes (13.8%), mass (22.1%), other (11.7%) and unknown (32%). The most common surgical treatment was capsulectomy and breast implant removal. In 97% of the cases, ALK was negative and 3% were positive. The most common marker was CD30. The most common chemotherapy regimen was CHOP. Three patients died. Two of the patients had extracapsular extension of the disease and breast cancer history. Lymphoma related with the breast implant was a different type of lymphoma, and in most cases, it was less aggressive. The disease was confined to the capsule. Few patients developed aggressive disease, were extracapsular and showed bad prognosis.
authors.affiliation: a Mexican Society of Plastic , Aesthetic and Reconstructive Surgery , Mexico City , Mexico.
authors.forename: Guillermo
authors.initials: G
authors.lastname: Ramos-Gallardo
authors.affiliation: a Mexican Society of Plastic , Aesthetic and Reconstructive Surgery , Mexico City , Mexico.
authors.forename: Jesús
authors.initials: J
authors.lastname: Cuenca-Pardo
authors.affiliation: a Mexican Society of Plastic , Aesthetic and Reconstructive Surgery , Mexico City , Mexico.
authors.forename: Eugenio
authors.initials: E
authors.lastname: Rodríguez-Olivares
authors.affiliation: a Mexican Society of Plastic , Aesthetic and Reconstructive Surgery , Mexico City , Mexico.
authors.forename: Rufino
authors.initials: R
authors.lastname: Iribarren-Moreno
authors.affiliation: a Mexican Society of Plastic , Aesthetic and Reconstructive Surgery , Mexico City , Mexico.
authors.forename: Livia
authors.initials: L
authors.lastname: Contreras-Bulnes
authors.affiliation: a Mexican Society of Plastic , Aesthetic and Reconstructive Surgery , Mexico City , Mexico.
authors.forename: Alfonso
authors.initials: A
authors.lastname: Vallarta-Rodríguez
authors.affiliation: a Mexican Society of Plastic , Aesthetic and Reconstructive Surgery , Mexico City , Mexico.
authors.forename: Marco
authors.initials: M
authors.lastname: Kalixto-Sanchez
authors.affiliation: a Mexican Society of Plastic , Aesthetic and Reconstructive Surgery , Mexico City , Mexico.
authors.forename: Claudia
authors.initials: C
authors.lastname: Hernández
authors.affiliation: b Universidad de Guadalajara , Puerto Vallarta , Mexico.
authors.forename: Ricardo
authors.initials: R
authors.lastname: Ceja-Martinez
authors.affiliation: a Mexican Society of Plastic , Aesthetic and Reconstructive Surgery , Mexico City , Mexico.
authors.forename: Cesar
authors.initials: C
authors.lastname: Torres-Rivero
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism; D019928:Breast Implantation / Q000009:adverse effects* / Q000379:methods; D018427:Breast Implants / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000601:surgery*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015994:Incidence; D017728:Lymphoma, Large-Cell, Anaplastic / Q000453:epidemiology* / Q000209:etiology* / Q000378:metabolism / Q000628:therapy; D008408:Mastectomy; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000378:metabolism; D012307:Risk Factors; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014408:Biomarkers, Tumor; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases; D011241:Prednisone
keywords: ALCL; BIA-ALCL; adverse event; anaplastic Lymphoma giant cells; breast implants; breast prostheses; lymphoma no Hodgkin